Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine".

Autor: Priti K; Department of Cardiology, JLN Medical College, Ajmer, Rajasthan, India., Ranwa BL; Department of Cardiology, JLN Medical College, Ajmer, Rajasthan, India., Gokhroo RK; Department of Cardiology, JLN Medical College, Ajmer, Rajasthan, India., Kishore K; Department of Cardiology, JLN Medical College, Ajmer, Rajasthan, India., Bisht DS; ACE Heart and Vascular Institute, Mohali, Punjab, India., Gupta S; Escorts Heart Hospital, New Delhi, India.
Jazyk: angličtina
Zdroj: Cardiovascular therapeutics [Cardiovasc Ther] 2017 Aug; Vol. 35 (4).
DOI: 10.1111/1755-5922.12266
Abstrakt: Background: Atrioventricular (AV) blocks are of concern with the use of beta blockers in inferior wall myocardial infarction (MI). Ivabradine lowers heart rate with a lesser risk of AV blocks.
Objectives: To compare ivabradine with metoprolol in acute inferior wall MI in terms of feasibility, tolerability, and efficacy.
Methods: It was a prospective double-blind single-center randomized controlled study. Of 1032 patients with acute inferior wall MI, 468 eligible patients were randomized in 1:1 manner to ivabradine (group A) and metoprolol (group B). Intention to treat analysis of 426 patients (group A-232 and group B-232) was performed. The primary endpoint was 30-day incidence of major adverse cardiovascular events including death, reinfarction, complete heart block (CHB), and heart failure. Secondary endpoints included 30 days incidence of recurrent angina, readmission, first- or second-degree AV block, and tachyarrhythmias.
Results: Both the drugs decreased the mean heart rate to 62.22±2.95 (group A) vs 62.53±3.59 (group B) beats per minute (P=0.33). Ejection fraction improved in both the groups (5.15±1.93% in group A vs 5.52±2.18% in group B, P=0.065). The two groups did not differ significantly in their primary endpoints in terms of death (group A=1.72% vs group B=1.72%, OR=1.00, 95% CI=0.25-4.05, P=1.00), reinfarction (group A=0.86% vs group B=0.86%, OR=1.00, 95% CI=0.14-7.16, P=1.00), heart failure (group A=4.31% vs group B=2.59%, OR=1.70, 95% CI=0.61-4.75, P=0.31), or CHB (0% vs 2.59%, OR=0.07, 95% CI=0.00-1.34, P=0.08). There were no significant differences in the secondary endpoints of recurrent angina, readmission, and tachyarrhythmias except for more first- and second-degree AV blocks with metoprolol (12.93% vs 2.59%, OR=5.59, 95% CI=2.28-13.72, P=0.0002).
Conclusions: Ivabradine is well tolerated and equally effective as metoprolol in acute inferior wall ST elevation myocardial infarction patients for lowering the heart rate with lesser risk of AV blocks.
(© 2017 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje